drugset / Trial / NCT01450839

E2022 Patch Formulation Multiple Dose Study

NCT01450839

Phase 1 Completed 16 enrolled Eisai Inc.
RandomizedCrossoverTriple-blindTreatment

Summary

This study is to evaluate the safety and tolerability of a E2022 16 mg tape when applied repeatedly for 17 days to healthy elderly Japanese male subjects, using E2022 placebo tape as the control.

Timeline

Start
2011-09
Primary completion
2011-11
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Donepezil Small molecule 5 mg Topical
Subject Donepezil Small molecule 16 mg Topical

Indications

No indication recorded.